ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO448

Effect of Icodextrin on Volume and Metabolism: A Multicenter Clinical Study

Session Information

  • Home Dialysis - 2
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Li, Yao, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
  • Zhou, Zhu, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Background

Icodextrin is a novel peritoneal dialysis fluid that enhances fluid clearance. It works through the formation of colloidal osmotic pressure, so it maintains effective ultrafiltration for a longer period of time, and the incidence of ultrafiltration (UF) failure is much lower than that of glucose peritoneal dialysis solution.The aim of this study was to compare the changes in volume and metabolism of patients before and after icodextrin treatment, expecting more evidence to support the effectiveness of icodextrin.

Methods

After screening for inclusion and exclusion criteria, we included 20 cases of continuous ambulatory peritoneal dialysis (CAPD) patients from seven hospitals of Yunnan Province.These patients were given a 3-month long-stay nocturnal treatment with icodextrin .We compared nocturnal net UF, peritoneal creatinine clearance( Ccr), and body weight, BNP. And related metabolic parameters, including fasting blood glucose(FBG), cholesterol(TC), and triglycerides(TG), before and after icodextrin treatment.

Results

After 3 months of treatment with icodextrin, patients showed significant increase in nocturnal long-stay abdominal net UF and peritoneal Ccr. The mean nocturnal long-stay net abdominal UF was (57.78±257.63) ml at baseline and (681.85±168.23) ml after treatment (difference -624.07, 95% CI -742.69 --505.45, t=-11.10, P<0.001). The patient's peritoneal Ccr was (2.10±0.40) ml/min at baseline and (3.10±0.48) ml/min after treatment (difference -1.00, 95% CI -1.31-0.68, t=-6.72, P<0.001). Pre-treatment weight (64.98±10.79) kg Post-treatment weight (63.09±10.28) kg, (difference 1.89, 95% CI 0.58-3.21, t=3.05, P=0.007). After treatment, the patients' BNP decreased, but the difference was not statistically significant (P>0.05); FBG, TG and TC increased afterward, but the mean values were still in the normal range, and the difference was not statistically significant (P>0.05).

Conclusion

In this study, icodextrin was found to increase UF and peritoneal Ccr as well as improve volume control in patients. It can remove more water and reduce patients' body weight.But no significant effect of icodextrin in improving glycolipid metabolism and lowering BNP has been detected for the time being, and the effect of icodextrin on cardiac function needs to be further explored, and its long-term effects and potential application in specific patient groups need to be further investigated.

Funding

  • Government Support – Non-U.S.